uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City
26 sept. 2016 09h18 HE
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 26, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that Matt Kapusta, interim chief...
uniQure Announces Management and Board Changes
22 sept. 2016 16h18 HE
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its Board of Directors has...
uniQure Receives NASDAQ Deficiency Letter Related to Board Composition
16 sept. 2016 07h13 HE
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 16, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has received a letter from...
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress
25 août 2016 16h18 HE
|
uniQure
~ Progress Across the Pipeline
~ Additional data on AMT-060 in Hemophilia B Expected Later this Year
~Data from Sanfilippo B and Parkinson's Disease Studies Expected in Q1 2017
~Strong Balance...
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress
25 août 2016 16h05 HE
|
uniQure
~ Progress Across the Pipeline~ Additional data on AMT-060 in Hemophilia B Expected Later this Year~Data from Sanfilippo B and Parkinson’s Disease Studies Expected in Q1 2017~Strong Balance Sheet to...
uniQure to Present at Upcoming Investor Conferences in September
17 août 2016 07h12 HE
|
uniQure
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that members of its leadership team will...
uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect
27 juil. 2016 14h27 HE
|
uniQure
--Data from Low-Dose Cohort of AMT-060 Clinical Trial Continues to Show Durability and Therapeutically Relevant Factor IX (FIX) Activity in Severe, Older Patients with Advanced Joint Disease and...
uniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress
11 juil. 2016 13h54 HE
|
uniQure
AMSTERDAM, The Netherlands, July 11, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that updated data from its ongoing Phase I/II clinical study...
uniQure Appoints Jonathan Garen as Chief Business Officer
07 juil. 2016 06h43 HE
|
uniQure
AMSTERDAM, the Netherlands, July 7, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer....
uniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications
27 juin 2016 06h30 HE
|
uniQure
AMSTERDAM, the Netherlands, June 27, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Maria E. Cantor as Senior Vice President,...